Nucleic acid detection methods

• US 5,753,439 A
• Filed: 05/19/1995
• Issued: 05/19/1998
• Est. Priority Date: 05/19/1995
• Status: Expired due to Fees

• Current Assignee: Boston University Trustee
• Original Assignee: Trustees of Boston University
• Inventors: Szafranski, Przemyslaw, Yaar, Ron, Cantor, Charles R., Smith, Cassandra L.
• Primary Examiner(s): Jones, W. Gary
• Assistant Examiner(s): REES, DIANE
• Application Number:
  US08/446,102
• Time in Patent Office: 1,096 Days
• Field of Search: 435/6, 435/5, 435/91.2, 536/24.3-24.33, 536/26.6
• US Class Current: 435/6.12
• CPC Class Codes: C12Q 1/6823 Release of bound markers
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 2521/307 Single strand endonuclease
• CPC Class Codes: C12Q 2525/151 repeat or repeated sequences, e.g. VNTR, microsatellite, concatemer
• CPC Class Codes: C12Q 2535/131 Allele specific probes
• CPC Class Codes: C12Q 2537/1376 Displacement by an enzyme
• CPC Class Codes: C12Q 2565/501 being an array of oligonucleotides

Abstract

The invention relates to methods for rapidly determining the sequence and/or length a target sequence. The target sequence may be a series of known or unknown repeat sequences which are hybridized to an array of probes. The hybridized array is digested with a single-strand nuclease and free 3'"'"'-hydroxyl groups extended with a nucleic acid polymerase. Nuclease cleaved heteroduplexes can be easily distinguish from nuclease uncleaved heteroduplexes by differential labeling. Probes and target can be differentially labeled with detectable labels. Matched target can be detected by cleaving resulting loops from the hybridized target and creating free 3-hydroxyl groups. These groups are recognized and extended by polymerases added into the reaction system which also adds or releases one label into solution. Analysis of the resulting products using either solid phase or solution. These methods can be used to detect characteristic nucleic acid sequences, to determine target sequence and to screen for genetic defects and disorders. Assays can be conducted on solid surfaces allowing for multiple reactions to be conducted in parallel and, if desired, automated.

Claims

1. A method for detecting a target sequence within a nucleic acid comprising the steps of:

a) hybridizing the nucleic acid to an array of probes wherein each probe comprises a 5'"'"'-region complementary to the 3'"'"'-region of said nucleic acid, a 3'"'"'-region complementary to the 5'"'"'-region of said nucleic acid and an internal variable region which is unique to each probe to form a hybridized array;

b) digesting the hybridized array with a single-strand specific nuclease;

c) treating said array with a nucleic acid polymerase; and

d) identifying a probe with an internal variable region complementary to the target sequence.

2. The method of claim 1 wherein the target sequence and the internal variable region of each probe comprise a plurality of repeat sequences.

3. The method of claim 2 wherein the plurality comprises between about 2 to about 2000 repeat sequences.

4. The method of claim 2 wherein the repeat sequences are each between about 2 to about 25 nucleotides in length.

5. The method of claim 1 wherein the nucleic acid is DNA, RNA, PNA or modifications thereof.

6. The method of claim 1 wherein the nucleic acid is labeled at a 5'"'"'-terminus or a 3'"'"'-terminus with a chemical moiety.

7. The method of claim 6 wherein the chemical moiety is selected from the group consisting of radioisotope, stable isotopes, luminescent and electroluminescent chemicals, fluorescent chemicals, chromogenic chemicals, metals, coupling agents and magnetic agents.

8. The method of claim 1 wherein the nucleic acid is from a biological sample.

9. The method of claim 8 wherein the biological sample is a sample of biomass, bodily tissue, bodily fluid or combination thereof.

10. The method of claim 1 wherein the nucleic acid is a polymerase chain reaction product.

11. The method of claim 1 wherein the 5'"'"'-region and the 3'"'"'-region are each between about 15 to about 100 nucleotides in length.

12. The method of claim 1 wherein the variable region comprises a plurality of repeat sequences.

13. The method of claim 12 wherein the plurality comprises between about 2 to about 2000 repeat sequences.

14. The method of claim 13 wherein the repeat sequences are each between about 2 to about 25 nucleotides in length.

15. The method of claim 1 wherein the variable region is variable in sequence or length.

16. The method of claim 15 wherein the length is between about 10 to about 2000 nucleotides.

17. The method of claim 1 wherein the variable region comprises a sequence of neutral bases.

18. The method of claim 17 wherein the neutral bases are inosine bases.

19. The method of claim 1 wherein the nucleic acid is labeled at a 5'"'"'-terminus or a 3'"'"'-terminus with a chemical moiety.

20. The method of claim 19 wherein the chemical moiety is selected from the group consisting of radioisotope, stable isotopes, fluorescent chemicals, luminescent and electroluminescent chemicals, chromogenic chemicals, metals, coupling agents and magnetic agents.

21. The method of claim 1 wherein the nucleic acid and the probes are labeled with different chromogenic chemicals.

22. The method of claim 1 wherein the array is fixed to a solid support.

23. The method of claim 22 wherein the solid support is selected from the group consisting of plastics, glasses, ceramics, metals, resins, gels, membranes, chips and combinations thereof.

24. The method of claim 1 wherein the single-strand specific nuclease is S1 nuclease, mung bean nuclease, ribonuclease A or ribonuclease T1.

25. The method of claim 1 wherein the nucleic acid polymerase is a DNA polymerase, a reverse transcriptase, an RNA polymerase or a thermostable polymerase.

26. The method of claim 1 wherein the target sequence detected is indicative of a disorder.

27. The method of claim 1 wherein the disorder is myotonic dystrophy, Huntington'"'"'s disease, Kennedy disease or Fragile X syndrome.

56. The method of claim 1 wherein the probes are fixed at discrete sites to a solid support.

28. A method for determining a length of a target sequence within a nucleic acid comprising the steps of:

a) hybridizing the nucleic acid to an array of probes wherein each probe comprises a 5'"'"'-region complementary to the 3'"'"'-region of said nucleic acid, a 3'"'"'-region complementary to the 5'"'"'-region of said nucleic acid, and an internal variable region which is unique to each probe to form a hybridized array;

b) digesting the hybridized array with a single-strand specific nuclease;

c) treating said array with a nucleic acid polymerase; and

d) determining the length of the target sequence.

29. The method of claim 28 wherein the nucleic acid is a PCR product.

30. The method of claim 28 wherein the internal variable region comprises a plurality of contiguous identical bases.

31. The method of claim 30 wherein the plurality of contiguous identical bases are inosine residues or modifications of inosine residues.

32. A method for determining the number of repeat sequences within a target sequence of a nucleic acid comprising the steps of:

a) hybridizing the nucleic acid to an array of probes wherein each probe comprises a 5'"'"'-region complementary to the 3'"'"'-region of said nucleic acid, a 3'"'"'-region complementary to the 5'"'"'-region of said nucleic acid and an internal region containing one or more repeat sequences which is unique to each probe to form a hybridized array;

b) digesting the hybridized array with a single-strand specific nuclease;

c) treating said array with a nucleic acid polymerase; and

d) identifying a probe containing an internal variable region complementary to the target sequence and determining the number of repeat sequences within the target sequence.

33. The method of claim 32 wherein the nucleic acid is from a mammal, an insect or a microorganism.

34. The method of claim 32 wherein the array comprises greater than R different probes and R is the number of repeat sequences in the target sequence.

35. The method of claim 32 wherein the array comprises a fraction of R probes and R is the number of repeats in the target sequence.

36. The method of claim 35 wherein the steps a, b, and c are repeated using a different fraction of the array.

37. The method of claim 32 wherein the internal region is between about 10 to about 2000 nucleotides in length.

38. The method of claim 32 wherein the repeat sequences are each between about 2 to about 10 nucleotides in length.

39. The method of claim 32 wherein the repeat sequences are contiguous.

40. The method of claim 32 wherein the variable region comprises a sequence of neutral bases.

41. The method of claim 32 further comprising the step of pooling a collection of different nucleic acids and hybridizing the collection to the array.

57. The method of claim 40, wherein the neutral bases are inosine residues or modifications of inosine residues.

58. The method of claim 57 wherein the probes of the array are hybridized to the fixed nucleic acids sequentially.

42. A method for screening a patient suspected of having a genetic disorder characterized by the presence or absence of a target repeat sequence comprising the steps of:

a) amplifying a nucleic acid from a patient sample;

b) hybridizing said nucleic acid to an array of probes wherein each probe comprises a 5'"'"'-region complementary to the 3'"'"'-region of said nucleic acid, a 3'"'"'-region complementary to the 5'"'"'-region of said nucleic acid and an internal variable region which is unique to each probe to form a hybridized array;

c) digesting the hybridized array with a single-strand specific nuclease;

d) treating said array with a nucleic acid polymerase; and

e) identifying a probe containing an internal variable region complementary to the target repeat sequence and detecting the presence or absence of the genetic disorder.

43. The method of claim 42 wherein the patient is a mammal.

44. The method of claim 43 wherein the mammal is a human.

45. The method of claim 42 wherein the genetic disorder is myotonic dystrophy, Huntington'"'"'s disease, Kennedy disease or Fragile X syndrome.

46. The method of claim 42 wherein the nucleic acid is amplified by polymerse chain reaction.

47. The method of claim 42 further comprising the step of pooling a collection of nucleic acids from different patients, hybridizing the collection to the array and determiinig the presence or absence of the genetic disorder in any of the patients.

48. An array of at least 10 probes wherein each probe comprises an identical 5'"'"'-region, an identical 3'"'"'-region and a variable internal region wherein said variable region comprises one or more repeat sequences which is unique to each probe.

49. The array of claim 48 wherein the repeat sequence comprises a sequence of inosine residues.

50. The array of claim 48 which comprises between about 50 to about 5000 different probes.

51. The array of claim 48 which comprises greater than 5000 different probes.

52. The array of claim 48 which comprises DNA, RNA, PNA or modifications thereof.

53. The array of claim 48 wherein the probes are labeled with a detectable label.

54. The array of claim 53 wherein the detectable label is a chromagenic chemical.

55. The array of claim 48 which is fixed to a solid support.